Monk Mind™ Capsules

A double-blind, placebo-controlled randomized trial recruited 107 healthy adults (62 completed) and gave 2 × 150 mg/day of KeenMind® (CDRI 08), an extract standardized to not less than 55% bacosides, for 90 days. The Bacopa group improved on the working-memory factor, specifically spatial working-memory accuracy, and made fewer false-positive errors on a rapid visual information-processing task.

A randomized, double-blind, placebo-controlled 42-month pilot trial in 118 cognitively intact adults aged 85 and older tested 240 mg/day of a Ginkgo extract independently verified to contain at least 24% flavone glycosides and 6% terpene lactones. The main intention-to-treat analysis reported p=0.06 for progression to mild impairment and p=0.05 for memory decline. A secondary analysis adjusted for adherence showed lower risk of progression to mild impairment (HR 0.33, p=0.02). Ischemic strokes and TIAs were recorded more often in the Ginkgo group (p=0.01).

The Ginkgo Evaluation of Memory randomized, double-blind, placebo-controlled trial followed 3,069 adults aged 75 and over with normal cognition or mild cognitive impairment for a median of 6.1 years on 120 mg of Ginkgo extract twice daily. The trial reported hazard ratios of 1.12 (P=.21) for all-cause dementia and 1.16 (P=.11) for Alzheimer disease, and adverse-effect profiles were similar to placebo.

A multicentre, double-blind, randomized, placebo-controlled 24-week trial in 410 outpatients with mild-to-moderate dementia and neuropsychiatric symptoms tested the branded extract EGb 761® at 240 mg once daily. Cognition (SKT) improved by 2.2 points versus 0.3 on placebo and neuropsychiatric scores (NPI) by 4.6 versus 2.1 (both p<0.001).

A randomized, double-blind, placebo-controlled trial in 90 patients with vascular cognitive impairment compared 120 mg/day or 60 mg/day of EGb 761® (24% flavonol glycosides, 6% terpenes) with placebo for 6 months. Ginkgo improved the Clinical Global Impression score versus placebo (P=0.038), and adverse reactions were less common than on placebo.

A meta-analysis of randomized, placebo-controlled trials of standardized Bacopa extracts taken for at least 12 weeks included 9 studies with 518 participants. Pooled data from 437 participants showed faster Trail B performance (-17.9 ms) and shorter choice reaction time (10.6 ms), suggesting Bacopa may improve cognition, particularly speed of attention.